(Press-News.org) Copenhagen, Denmark: A small study with couples experiencing unexplained infertility suggests that a hormone treatment could increase the chances of having a baby.
The trial, presented today (Monday) at the 39th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) [1], compared couples trying to conceive naturally with couples where the woman used a vaginal progesterone treatment during the second half of her menstrual cycle.
The researchers say a larger trial is now warranted but, given the treatment is safe and low-cost, it could ultimately benefit many people living with infertility around the world.
The study was presented by Dr Claudia Raperport, a researcher at Queen Mary University of London, (UK). It included 143 couples who had unexplained infertility, a diagnosis that affects around one-third of couples referred to fertility services.
All the participants used ovulation test kits to plan intercourse for three menstrual cycles. Half of the women were given treatment of 400 milligrams of progesterone via a twice-daily vaginal suppository for 14 days.
Among the women treated with progesterone, 11 out of 72 (15.3%) had babies. Among the women who were not treated, 5 out of 71 (7.0%) had babies. Although the birth rate was more than doubled with treatment, the small numbers mean that this could have happened by chance.
Among the women treated with progesterone who became pregnant, the rate of miscarriage was 20%, compared with 40% in the untreated group. Among women who took progesterone according to the treatment protocol (throughout the second half of their menstrual cycle and early pregnancy with no breaks), there were no miscarriages. Again, the numbers are too small for researchers to be sure these results did not happen by chance.
Vaginal progesterone has been safely used for over 30 years with minimal side effects alongside other fertility treatments such as IVF. The cost for three months of treatment would be around €200 or less.
Dr Raperport said: “The cost of progesterone is minimal compared to the cost of IVF and other fertility treatments. It also carries far less clinical risk, and physical and emotional burden for the couples involved.
“We need to do further research to prove these results in a larger group of people, but this trial suggests a potential treatment for couples with unexplained fertility. Given its safety and low price, there is no harm in offering this treatment in the meantime.”
It is well established that progesterone levels increase in the second half of the menstrual cycle to help prepare the lining of the womb to receive a fertilised egg. Women are usually offered a test to check the levels of progesterone in their blood. However, previous research in women experiencing infertility suggests that even when levels of progesterone are high in the blood, this does not always correspond with the changes to the womb lining that are needed for a fertilised egg to implant.
“It could be that treating women with vaginal progesterone is helping the womb to become more receptive to a fertilised egg,” she added.
The chair of ESHRE, Professor Carlos Calhaz-Jorge from the Northern Lisbon Hospital Centre and the Hospital de Santa Maria in Lisbon (Portugal), was not involved in this research. He said: “Lots of research has focused on using progesterone to prevent miscarriage once pregnancy has been established. This study indicates that progesterone could also be used from the time a woman ovulates to help a fertilised egg implant in the womb in cases of unexplained infertility. If it is proven in a larger study, this treatment could reduce miscarriage and increase the chances of having a baby for those couples with unexplained infertility. Given the low cost of this treatment, it has enormous potential to help some couples avoid more complex treatments, particularly those living in parts of the world where fertility treatments like IVF are unaffordable or unavailable.”
Dr Raperport is planning to run a second trial with more couples at several hospitals and is currently seeking funding for this project.
(ends)
[1] Presentation no: O-023, “‘The PiNC Trial’: Progesterone in Natural Cycles for the treatment of unexplained infertility” presented by Claudia Raperport, Session 05: Trust the menstrual cycle – progesterone or not? Hall D4, 10.30 hrs CEST, Monday 26 June 2023.
Notes for editors
According to the UK Academy of Medical Science’s press release labelling system, this is a non-peer reviewed randomised controlled trial in people.
Funding: The study was registered on the NIHR portfolio, providing a small amount of income for the hospital, medication and ovulation and pregnancy tests were provided by LD Collins Ltd and SPD Spark Ltd.
When obtaining outside comment, journalists are requested to ensure that their contacts are aware of the embargo on this release.
For further information, contact:
Kerry Noble
Email: kerry_noble@hotmail.com
Mobile: +44 (0)7446 869 433
Emma Mason
Email: wordmason@mac.com
Mobile: +44 (0)7711 296986
Sophie Goodchild
Email: goodchildsophie@hotmail.com
Mobile: +44 (0)7767 325595
Laura Rossignoli at ESHRE
Email: Laura@eshre.eu
Mobile: +32 (0)499 92 32 49
The European Society of Human Reproduction and Embryology (ESHRE) is a European non-profit organisation with international membership, whose main mission is to promote the study and research of reproductive science and medicine as well as the treatment of infertility. Established in 1984, the Society now comprises more than 9.000 members and has become the leading Society in reproductive science and medicine worldwide. Our members are medical professionals, scientists and researchers working in reproductive science, reproductive medicine and embryology. We work in close partnership with the patient organisation Fertility Europe. The ESHRE annual meeting attracts over 11,000 clinicians, researchers, scientists, exhibitors. In 2022, participants from 130 countries attended. Seven of the top ten countries represented were European.
END
Cheap and safe hormone treatment shows promise for couples with unexplained infertility
2023-06-26
ELSE PRESS RELEASES FROM THIS DATE:
50-million-year-old katydid fossil reveals muscles, digestive tract, glands and a testicle
2023-06-26
CHAMPAIGN, Ill. — 50 million years ago in what is now northwestern Colorado, a katydid died, sank to the bottom of a lake and was quickly buried in fine sediments, where it remained until its compressed fossil was recovered in recent years. When researchers examined the fossil under a microscope, they saw that not only had many of the insect’s hard structures been preserved in the compressed shale, so had several internal organs and tissues, which are not normally fossilized.
They describe their findings in the journal Palaeoentomology.
“Katydids ...
Are more babies born if embryos are cultured for three or five days in the lab? Largest randomised clinical trial to date suggests that age matters
2023-06-26
Copenhagen, Denmark: Women are just as likely to give birth to live babies after fertility treatment if embryos are transferred to their wombs three days after fertilisation in the laboratory rather than five. However, the women’s age can affect the outcomes, according to new research presented to the 39th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) [1].
Dr Simone Cornelisse, a researcher and resident in obstetrics and gynaecology at Radboud University Medical Center, Nijmegen (The Netherlands), told the conference that among 1202 women from 21 Dutch fertility centres who were randomly assigned to have embryos transferred to their wombs ...
Cancer risk among women with polycystic ovary syndrome doubles after menopause
2023-06-26
Copenhagen, Denmark: Women with polycystic ovary syndrome (PCOS) are not at any greater risk of ovarian cancer than those without the common hormone condition, say researchers. However, those with PCOS who have been through the menopause are more than twice as likely to be diagnosed with ovarian cancer.
The data based on nearly two million women is presented today (Monday) at the 39th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE) [1]. The research is also published simultaneously in the International Journal of Cancer [2].
This ...
Humans’ evolutionary relatives butchered one another 1.45 million years ago
2023-06-26
Researchers from the Smithsonian’s National Museum of Natural History have identified the oldest decisive evidence of humans’ close evolutionary relatives butchering and likely eating one another.
In a new study published today, June 26, in Scientific Reports, National Museum of Natural History paleoanthropologist Briana Pobiner and her co-authors describe nine cut marks on a 1.45 million-year-old left shin bone from a relative of Homo sapiens found in northern Kenya. Analysis of 3D models of the fossil’s surface revealed ...
Childhood cancer: Vulnerability in the immune response against metastases discovered
2023-06-26
Scientists led by Sabine Taschner-Mandl, PhD, St. Anna Children's Cancer Research Institute, and Nikolaus Fortelny, PhD, Paris Lodron University of Salzburg, are the first to analyze bone marrow metastases from childhood tumors of the nervous system using modern single-cell sequencing analysis. It turns out that cancer cells prevent cells in their environment from fighting the tumor – a process that could be reversed with medication. The findings were published in the renowned journal Nature Communications.
Neuroblastoma is the most ...
Novel study deepens knowledge of treatment-resistant hypertension
2023-06-26
For many patients with hypertension—an elevated blood pressure that can lead to stroke or heart attack—medication keeps the condition at bay. But what happens when medication that physicians usually prescribe doesn’t work? Known as apparent resistant hypertension (aRH), this form of high blood pressure requires more medication and medical management.
Novel research from investigators in the Smidt Heart Institute at Cedars-Sinai, published today in the peer-reviewed journal Hypertension, found that aRH prevalence was lower in ...
Progesterone decreases night sweats & improves sleep in perimenopausal women
2023-06-26
New controlled trial research documents that Progesterone (micronized, oral) is effective at decreasing night sweats and improving sleep in perimenopausal women who have menstruated in the last 1-year. Perimenopausal women most want treatment for these two symptoms.
Current guidelines prescribe Menopausal Hormone Therapy (MHT) for disturbing hot flushes/flashes or night sweats (vasomotor symptoms, VMS) in all women younger than 60 years.
“This guideline assumes that hormone levels and symptoms are the same in the early years of ...
What are the endometrial cancer risks and trends among different African descent populations?
2023-06-26
Study reveals some distinctions between Black women in the US and the French Caribbean but increasing trends for aggressive forms in both regions.
Compared with white women, Black women have elevated risks of being diagnosed with advanced uterine cancer—also known as endometrial cancer—and of developing aggressive tumors. Researchers recently compared the incidence and trends for endometrial cancer, both overall and by subtype, between African descent women in Florida and women in the French Caribbean—specifically, the islands of Martinique and Guadeloupe. The findings are published by Wiley online ...
Endometrial cancer risk and trends among distinct African-descent populations
2023-06-26
MIAMI, FLORIDA (EMBARGOED UNTIL 3:01 AM ET Monday, June 26, 2023) – Current evidence indicates Black women in the U.S. are at greater risk of developing advanced uterine cancer, also known as endometrial cancer, and of developing its more aggressive form – non-endometroid cancer – than white women.
But research to date has mostly studied Black women as a homogenous group, and there is limited data about specific African-descent subpopulations worldwide. That is until now.
A new study by researchers with Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine compared both the overall incidence and trends for endometrial ...
New Orleans infection preventionists adapt adult protocols to reduce infections in babies
2023-06-26
Orlando, Fla., June 26, 2023 – Facing persistent cases of hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) during the pandemic, the infection prevention and control (IPC) team at Children’s Hospital New Orleans developed an inexpensive nasal decolonization regimen previously used only in their adult patients that decreased rates of MRSA by 50 percent. Their results are being presented at the Association for Professionals in Infection Control and Epidemiology’s (APIC’s) Annual Conference in Orlando Florida, June 26-28.
Without a lot of scientific literature on nasal decolonization in the pediatric population to guide them, Infection Preventionist ...